CTMX - Company ID 0001501989
CytomX Therapeutics, Inc. trades as CTMX. In its fiscal 2025 annual report the company posted revenue of $76.20M, down 44.8% from the prior year and net income of -$17.37M. This page tracks CytomX Therapeutics, Inc. through 770 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years CytomX Therapeutics, Inc.'s revenue grew from $15.04M to $76.20M, a compound annual growth rate of 19.8%. Net profit margin expanded from -391.5% to -22.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-30 |
The largest companies sharing CytomX Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
CytomX Therapeutics, Inc. reported revenue of $76.20M for fiscal year 2025, a decrease of 44.8% year over year.
In its latest fiscal year CytomX Therapeutics, Inc. reported a net loss of $17.37M.